ISL1 Antibodies

Insulin gene enhancer protein ISL-1 (ISL1)

Recognizes and binds to the consensus octamer binding site 5'-ATAATTAA-3' in promoter of target genes. Plays a fundamental role in the gene regulatory system essential for retinal ganglion cell (RGC) differentiation.

Cooperates with the transcription factor POU4F2 to reach maximal levels of expression of RGC target genes and RGC fate specification in the developing retina. Involved in the specification of motor neurons in cooperation with LHX3 and LDB1.

Gene Information

Human
Gene Name:	ISL1
Uniprot:	P61371
Entrez:	3670

Family

Belongs to:
No superfamily

Alternative Names

insulin gene enhancer protein ISL-1; ISL LIM homeobox 1; ISL1 transcription factor, LIM/homeodomain; ISL1 transcription factor, LIM/homeodomain, (islet-1); ISL1; Isl-1; Islet1; Islet-1

Molecular Weight

Mass (kDA):
39.036 kDA

Genomic Context

Human
Location:	5q11.1
Sequence:	5; NC_000005.10 (51383448..51394730)

Tissue Specificity

Expressed in subsets of neurons of the adrenal medulla and dorsal root ganglion, inner nuclear and ganglion cell layers in the retina, the pineal and some regions of the brain.

Subcellular Localizations

Nucleus.

Diseases

• Diabetes Mellitus
• Congenital Heart Defects
• Nervousness
• Heart Diseases
• Diabetes Mellitus, Non-insulin-dependent
• Neoplasms
• Pituitary Diseases
• Hypoplasia
• Malignant Neoplasms
• Congenital Abnormality
• Tissue Adhesions
• Carcinoma
• Pancreatic Neoplasm

• Impaired Glucose Tolerance
• Protrusion
• Insulinoma
• Myocardial Infarction
• Congenital Heart Disease
• Idiopathic Pneumonia Syndrome
• Crest Syndrome

Interacting Proteins

• ZNF511

Pathways

• Cell Differentiation
• Heart Development
• Neurogenesis
• Secretion
• Regeneration
• Pathogenesis
• Cell Cycle
• Cell Development
• Pancreas Development
• Neuron Differentiation
• Cell Adhesion
• Heart Formation
• Insulin Secretion

• Cell Proliferation
• Tube Formation
• Neuron Development
• Axon Guidance
• Innervation
• Regionalization
• Localization

PTMs

• Phosphorylation

• Methylation

• Ubiquitination

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/ISL1

What Are the Best Uses of the ISL1 Marker?

What are the Best Uses of ISL1? This article will explain the various uses this biomarker has, including how it regulates SNAI1. ISL1 inhibits lipid synthesis while promoting cell proliferation. ISL1 can be used as a biomarker for pancreatic neuroelectronic NETs. It is a versatile and useful biomarker that is available to scientists around world.

SNAI1 is subject to ISL1

ISL1 has been implicated in the regulation and function of SNAI1. Boster Bio studies have shown that ISL1 lowers the amount ISL1 in the heart of rats. It also decreases the expression KDM6B gene which is essential for SHF migration survival and differentiation. In the absence of ISL1, mice exhibit decreased atrial tissue and shortened OFT. Mice without this protein are also susceptible to developmental arrest at E9.5, and eventually die at E10.5.

ISL1 plays a dual role in endothelial differentiate and angiogenesis. It also mediates EndMT. These functions are difficult to reconcile until we gain more insight into the process. ISL1 seems to be a valuable tool for exploring how ISL1 regulates SNAI1 within Boster Bio. This research will provide a basis for further investigation of how ISL1 affects the development of sarcomeres.

The enrichment tests look for differentially expressed targets that are overrepresented to identify potential regulators. It also identifies targets whose direction changes in accordance with activation/repression. This test also identifies transcription elements that are related Neurogenins through direct gene regulation interactions. Although the results of this study were not conclusive, they indicate that iNGN cell networks are much larger than previously thought.

ShRNAs targeting SNAI1 significantly decreased NEUROD1 expression in iNGN cells after transfection. NEUROD1–shRNA knockdown didn't inhibit neurogenesis. All three shRNAs produced significant morphological modifications in the day-four of iNGN neurons. NEUROD1–shRNA knockdown was also associated with an increase non-bipolar cell neural cells and a reduced soma volume in iNGN neurons.

ISL1 prevents lipid synthesis

Interacting with a KDM6B gene is one way ISL1 can suppress lipogenesis. This gene regulates SNAI1, a protein which inhibits lipid synthesis. This protein also has antilipogenic properties. But how does ISL1 inhibit lipid synthesis? To understand its mechanism, we first need to understand KDM6B.

The lipid-synthesis pathway is an important mechanism that produces sterols. This is important for your health. In this model, ISL1 and adenovirus both inhibit the formation of the sterols. Shanghai GenePharma Co. Ltd. derived the protein from infected cells with adenovirus. The cells were given the adenovirus at a ratio 1:10 and treated using ISL1, sh–SNAI1 and/or oe–KDM6B.

We identified ISL1 from rat tissues. The ISL1 gene was downregulated in T2DM rats, while basic biochemical markers such as the Wnt pathway and apoptosis-related genes were increased. T2DM rats had lower b-cell function and islet sensitivity in blood samples. An increase in phosphorylated ERK1/2 levels was also seen with MiR-128-3p. These results suggest that T2DM might be a potential therapeutic target.

Boster Bio ISL1 inhibitors lipid synthesis can be used to assess the role of ODIR1 for osteogenic differentiation of hUC–MSCs and OSX cell lines. It comes in a Liquid form, and can be tested in IHC/WB. The antibody reacts with both Human as Mouse RNA. This product can be used by scientists worldwide.

ISL1 promotes cell growth

Evidence is mounting that ISL1 regulates cell growth in many organs, including the stomach. Isl1 plays an important role in myogenesis (the process by which a cell takes on a myogenic fate). Chihara et al. studied Isl1 function during fetal esophageal development. The authors discovered that ES cells lacking Isl1 have a myogenic fate in their esophagus. Isl1 is also needed in the stomach and smooth muscles layers.

ISL1 is a growth factor that regulates a variety. It regulates the expression of cJun and other p-STAT3-mediated transcription factor factors that drive cell growth. Nkx2.1 is also controlled by ISL1. This gene is involved in early foregut epithelial formation. It has been associated with poor prognoses in gastric carcinoma.

ISL1 is also necessary for the development and maintenance of chromaffin cell in the adrenal gland. It is crucial for the progression of gastric carcinoma and plays an important role in the development and maintenance of these cells. It is also important in the development and progression of pancreatic carcinoma. It is still unclear what role ISL1 plays in the development of cancer. Its expression in cancer cells is also linked to its progression. This suggests that ISL1 is a key player in the progression of gastric cancer.

ISL1 regulates the expression and activity of several anti-apoptotic genes, which is in addition to its role as a regulator of fetal stomach development. ISL1 also decreases cell death in response to chemotherapy drugs such cisplatin. ISL1 promotes cell proliferation, but it also inhibits the production a number of other key factors in esophagus.

ISL1 is also essential for cardiac development, where it functions by transactivating the MEF2C and TBX20 promoters. CHD has been linked to loss-of-function mutations of ISL1 in humans. MEIS2 plays a crucial role in signalling retinoic Acid. It promotes ISL1 expression within other organs, including the heart and kidney.

ISL1 may be a biological sign for pancreatic and pancreaticNETs

To identify the proteins expressed in NETs, researchers examined four transcriptional factors. Although all four genes had significant differences in expression, NKX2.2 was high expressed in small intestinal and pancreatic NETs. However, none of the genes were detected in gastric network NETs. However, NKX2.2 can be found in more than half of the pancreatic NETs.

There is a growing body of evidence supporting the use of the ISL1 gene as a biomarker for pancreatic NETs. This gene encodes an antgen that can distinguish pancreatic and gastrointestinal endocrine tumors. However, ISL1 remains to be confirmed as a useful biomarker to detect pancreatic NTES.

Two types of tissue microarrays were used to measure transcriptional factors NKX2.2 in pNETs, PDX-1 and CDX-2. They also looked at PDX-1 expression within pancreatic NETs. PDX-1 expression in 40-75% was found to be positive. PDX-1 was expressed in most pancreatic NETs. However, it was also detected in rectal and duodenal NETs. ISL1 is also expressed by ductal epithelative cell, but it was not found in acinar.

Neuroendocrine cancers are heterogeneous, non-invasive tumors that arise in the pancreas. SEER data shows that up to 19% patients with NET present with liver metastases at the beginning. Although NETs can be responsive to biomarkers and are very sensitive, it remains difficult to determine which primary site. Several biomarkers have been tested in primary NETs, but their sensitivity and specificity vary among primary and metastatic NETs.

ISL1 and NK2 homeobox 2 are transcription factors that are expressed in beta cells. ISL1 and NK2 homeobox 2 are required for beta cell differentiation. ISL1 and Nkx2.2 are not related, but may be biological markers for pancreatic NETs. It may be useful to detect pancreatic NETs through this immunohistochemical staining.

PTF1A is another biomarker that has yet to been discovered. PTF1A can be expressed in normal and tumor cells. However, it is not specific to pancreatic NEOs. To determine the role of both proteins, more research must be done on a larger number of patients. Unfortunately, the current research is limited. One way to identify biomarkers in pNET is to use genetic testing and immunohistochemistry.